Pharmacovigilance fees: questions and answers

The European Medicines Agency (EMA) has published detailed questions-and-answers (Q&As) on the fees it charges pharmaceutical companies for carrying out pharmacovigilance activities. These explain how the different types of procedure-based and annual fees are calculated and levied, the availability of fee reductions and exemptions and the invoicing and payment procedures.

Please also refer to the ' PDF iconExplanatory note on pharmacovigilance fees payable to the EMA ' for further guidance on pharmacovigilance fees payable to the Agency.

If your question still remains unanswered, please submit your query by completing our dedicated form:

You can also download the PDF iconpharmacovigilance fees Q&A in PDF format.

1. Pharmacovigilance fees payable to the EMA under Regulation (EU) No 658/2014

2. Single assessment of periodic safety update reports (PSURs)

3. Assessment of imposed, non-interventional post-authorisation safety studies (PASS)

4. Assessment of pharmacovigilance-related referrals

5. Annual fee for information technology systems and literature monitoring

6. Fee reductions and exemptions

7. Information in Article 57 database and pharmacovigilance fees

8. Payment modalities

How useful was this page?

Add your rating
Average
1 rating